Media coverage about ImmunoGen (NASDAQ:IMGN) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ImmunoGen earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.7329056776122 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

Shares of ImmunoGen (IMGN) traded up $0.15 during midday trading on Friday, hitting $8.91. The stock had a trading volume of 3,698,904 shares, compared to its average volume of 3,318,036. The company has a debt-to-equity ratio of -0.03, a quick ratio of 2.78 and a current ratio of 2.81. The firm has a market capitalization of $1,158.51, a P/E ratio of -6.85 and a beta of 2.50. ImmunoGen has a fifty-two week low of $2.31 and a fifty-two week high of $10.04.

ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings data on Friday, February 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). The firm had revenue of $39.40 million during the quarter, compared to analyst estimates of $39.62 million. The company’s revenue for the quarter was up 185.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.39) EPS. equities research analysts forecast that ImmunoGen will post -0.97 earnings per share for the current year.

A number of equities analysts have commented on IMGN shares. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research note on Tuesday, October 31st. BidaskClub upgraded ImmunoGen from a “hold” rating to a “buy” rating in a research note on Thursday, January 18th. Cantor Fitzgerald restated a “hold” rating and issued a $5.00 target price on shares of ImmunoGen in a research note on Friday, November 3rd. Royal Bank of Canada restated an “outperform” rating and issued a $12.00 target price on shares of ImmunoGen in a research note on Thursday. Finally, HC Wainwright started coverage on ImmunoGen in a research note on Wednesday, January 31st. They issued a “buy” rating for the company. Two analysts have rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $7.83.

COPYRIGHT VIOLATION WARNING: “ImmunoGen (IMGN) Receives Daily Media Impact Rating of 0.20” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Insider Buying and Selling by Quarter for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with's FREE daily email newsletter.